Latest News

Frontline Adagrasib Plus Pembrolizumab Elicits Encouraging Clinical Activity in KRAS G12C+ Advanced NSCLC
Frontline Adagrasib Plus Pembrolizumab Elicits Encouraging Clinical Activity in KRAS G12C+ Advanced NSCLC

December 8th 2022

Concurrent adagrasib and pembrolizumab produced preliminary activity when administered as first-line treatment in patients with non–small cell lung cancer harboring a KRAS G12C mutation, irrespective of PD-L1 status, according to data from the KRYSTAL-1 phase 1b and the KRYSTAL-7 phase 2 cohorts.

Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer
Nivolumab-Based Therapy Drives Durable Responses in Recurrent/Metastatic Cervical Cancer

November 30th 2022

NT-I7/Pembrolizumab Combo Shows Clinical Efficacy in MSS CRC and Pancreatic Cancer Without Liver Metastasis
NT-I7/Pembrolizumab Combo Shows Clinical Efficacy in MSS CRC and Pancreatic Cancer Without Liver Metastasis

November 30th 2022

NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer
NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer

November 29th 2022

ARRY-614 Plus Immune Checkpoint Inhibition Can Induce Durable Responses in Advanced Solid Tumors
ARRY-614 Plus Immune Checkpoint Inhibition Can Induce Durable Responses in Advanced Solid Tumors

November 28th 2022

Video Series
Video Interviews
Podcasts

More News